Core Viewpoint - BYD's stock performance has been strong, with a 4.46% increase closing at 107.63 yuan, driven by positive news including the launch of the second-generation blade battery and fast-charging technology, and an upcoming smart driving technology conference [1] Group 1: Product Development - The second-generation blade battery and fast-charging technology have been launched, showing improvements in charging speed, energy density, lifespan, and safety compared to the first generation [3] - BYD plans to release 10 new models equipped with the second-generation blade battery, enhancing its product matrix amid rising oil prices, which could boost future sales [5] - The company is also focusing on solid-state battery development, maintaining a leading position globally in research breakthroughs, product maturity, and production line layout [10] Group 2: Market Expansion - Citigroup forecasts that BYD's domestic and export sales will expand monthly, reaching approximately 220,000 to 250,000 units by March 2026 [3] - BYD's overseas sales are expected to exceed 1 million units by 2025, accounting for about 20% of total sales, with significant orders from Argentina and Mexico totaling 100,000 electric vehicles [10] Group 3: Recruitment and Workforce - BYD is ramping up recruitment across various locations, with over 1,000 operational positions and more than 1,100 technical positions available, reflecting the company's growth and expansion plans [9] - The total number of employees at BYD has surpassed 900,000, making it the largest automotive company by workforce in the A-share market [9]

转自：智通财经 【荣昌生物：维迪西妥单抗新增乳腺癌适应症获批】《科创板日报》23日讯，荣昌生物(688331.SH)公 告称，公司自主研发的注射用维迪西妥单抗(商品名：爱地希®)用于治疗HER2低表达且存在肝转移的乳 腺癌新适应症获国家药监局批准，成为该药在国内获批的第四项适应症。该适应症适用于既往接受过系 统治疗或辅助化疗后12个月内复发的不可切除或转移性HER2低表达成人乳腺癌患者。此次获批基于一 项Ⅲ期临床试验，结果显示其在目标人群中具有良好疗效与安全性。公司提示，药品商业化受政策、市 场及竞争等多重因素影响，存在不确定性。 ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval for the registration of Ibuprofen Granules from the National Medical Products Administration, indicating a significant advancement in its product portfolio and potential market impact [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has successfully obtained the drug registration certificate for Ibuprofen Granules [1] - The registration application for Ibuprofen Granules was submitted to the Center for Drug Evaluation (CDE) in December 2023 and was accepted, leading to the approval in March 2026 [1] Group 2: Product Information - Ibuprofen Granules are indicated for the relief of mild to moderate pain, including headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea, as well as for fever caused by common colds or influenza [1] - The product is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025 edition) [1] Group 3: Market Insights - The sales revenue for ibuprofen-related formulations in Chinese public medical institutions is projected to be approximately RMB 4.4 billion in 2024 [1]

Core Viewpoint - The Bank of China has issued a warning regarding the need for enhanced risk prevention in the precious metals market due to increased geopolitical risks and significant price volatility in both domestic and international markets [1] Group 1: Market Conditions - Recent geopolitical tensions have led to heightened risks in the global precious metals market [1] - The prices of precious metals have experienced increased fluctuations influenced by multiple factors [1] Group 2: Customer Guidance - The Bank of China advises clients to take measures for market risk prevention to protect their interests in precious metals-related businesses [1] - Clients are encouraged to make rational investments based on their financial status and risk tolerance [1] - It is recommended to manage precious metal positions wisely and consider long-term investments to mitigate the impact of short-term price volatility [1]

Core Viewpoint - China Coal Energy (601898.SH) has received a registration notice from the China Interbank Market Dealers Association for its medium-term notes, allowing the company to issue up to RMB 5 billion in registered notes over the next two years [1] Group 1 - The registered amount for the medium-term notes is RMB 5 billion, valid for two years from the date of the registration notice [1] - The joint lead underwriters for the issuance are CITIC Securities Co., Ltd., Industrial and Commercial Bank of China, and China CITIC Bank [1] - The company plans to issue the medium-term notes in tranches during the registration period and will disclose the issuance results through approved channels [1] Group 2 - The company will issue the medium-term notes in accordance with the relevant rules and guidelines, including the Non-Financial Enterprise Debt Financing Instruments Registration and Issuance Rules [1] - The company is committed to ensuring proper information disclosure as required by the registration notice [1]

Core Viewpoint - Rongchang Biopharmaceutical has received approval from the National Medical Products Administration for the registration certificate of Vidisicimab (brand name: Aidiqi) for a new indication to treat HER2 low-expressing breast cancer with liver metastasis [1] Group 1 - Vidisicimab is now approved for its fourth indication in China [1] - The drug is indicated for adult patients with unresectable or metastatic HER2 low-expressing breast cancer (IHC 1+ or IHC 2+/ISH-) who have previously received at least one systemic treatment during the metastatic disease stage or have relapsed within 12 months after adjuvant chemotherapy [1]

Core Viewpoint - The Bank of China has issued a warning regarding the increased risks in the precious metals market due to heightened global geopolitical risks and significant price fluctuations [1] Group 1: Market Conditions - Recent geopolitical tensions have led to increased volatility in both domestic and international precious metal prices [1] - The bank emphasizes the need for clients to be aware of market risks and to take appropriate measures to safeguard their investments [1] Group 2: Investment Recommendations - Clients are advised to conduct rational investments based on their financial status and risk tolerance [1] - It is recommended to manage precious metal positions wisely and consider long-term investments to mitigate the impact of short-term price fluctuations [1]

Group 1 - The company announced a medium-term note registration amounting to RMB 5 billion [1] - The registration validity period is two years from the date of the acceptance registration notice [1]

Group 1 - UBS forecasts that the price of Chinese thermal coal for the year 2026 will be between 750 to 800 RMB per ton [1][6] - Price increases are expected to be concentrated in the summer replenishment window from May to June, influenced by high international energy prices and fluctuations in Indonesian supply [1][6] - In a tight supply scenario, prices may briefly test 900 RMB per ton, but sustained increases are unlikely due to China's rapid policy response capabilities [1][6] Group 2 - UBS projects QHD5500 coal prices for 2026, 2027, and 2028 to be 750 RMB, 720 RMB, and 670 RMB per ton respectively, reflecting a tightening global energy market and slight impacts from Indonesia's quota reductions [4] - The target price for China Shenhua (601088.SH) A-shares and China Shenhua (01088) H-shares is set at 48.6 RMB and 48 HKD respectively, with a "neutral" rating [4] - Yanzhou Coal Mining (01171) has a target price of 11.4 HKD, and Shaanxi Coal and Chemical Industry (601225.SH) has a target price of 22.8 RMB, both maintaining a "sell" rating due to current stock prices reflecting fundamentals [4]

Group 1 - UBS forecasts that the price of thermal coal in China will be between 750 to 800 RMB per ton for the full year of 2026, with price increases expected during the summer replenishment window in May and June [1] - The potential for prices to briefly test 900 RMB per ton exists under tight supply conditions, but sustained increases are unlikely due to China's responsive policy coordination capabilities [1] - The projected QHD5500 coal prices for 2026 to 2028 are 750 RMB, 720 RMB, and 670 RMB per ton, reflecting a slight impact from tightening global energy markets and Indonesia's quota reductions [1] Group 2 - China Shenhua (601088.SH) and China Shenhua (01088) have target prices set at 48.6 RMB and 48 HKD respectively, with a "neutral" rating [1] - Yanzhou Coal Mining (01171) has a target price of 11.4 HKD, and Shaanxi Coal and Chemical Industry (601225.SH) has a target price of 22.8 RMB, both maintaining a "sell" rating due to current stock prices reflecting fundamentals [1]